22CT015: CART 19-22 co-administration

AddtoAny
Share:

WATCH THIS PAGE

Subscribe to be notified of changes or updates to this page.

1 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

CAR T cell therapy has shifted the treatment landscape for pediatric and young adult patients with advanced B-cell leukemias. This study aims to treat patients with relapsed disease by administering two CART cell products, huCART19 and CART22-65s. The study will determine the safety and efficacy and usefulness of administering two CAR T cell products in patients with advanced B-cell leukemias.

This is a Phase 1/2b trial for the treatment of patients with either advanced or refractory B cell Acute Lymphoblastic Leukemia or B-lineage lymphoblastic lymphoma. Possible procedures include medical record review, apheresis, huCART19 infusion, blood draws, physical exams, imaging, and disease assessments through bone marrows and lumbar punctures. Overall, approximately 93 subjects will be enrolled on this clinical trial.

Who Do I Contact?

If you are interested in participating in the study or want to learn more please contact our study team at oncointake [at] chop.edu or 845-553-5358.

ClinicalTrials.gov Identifier

Eligibility & Criteria

IRB #:
22-020640
Official Title:
Use of Autologous Anti-CD22 CAR T Cells (CART22-65s) Co-administered with Humanized Anti-CD19 CAR T cells (huCART19) in Children and Young Adults with Relapsed or Refractory B-ALL
Study Phase:
Phase I
Phase II
Eligible Age Range:
0 Months - 29 Years
Gender:
All
Study Categories:

Visit Criteria

This study is open to enrollment and currently accepting new patients.